Alkem Laboratories Ltd (NSE: ALKEM) and Ipca Laboratories Ltd. (NSE: IPCALAB) are both listed in the Medicinal Chemicals and Botanical Products industry. Alkem Laboratories has a market capitalisation of ₹61,636 Cr and Ipca Laboratories ₹49,470 Cr, as of 9 Nov 2026. Their P/E ratios are 26.8 and 43.4 respectively. Return on equity is 17.56% for Alkem Laboratories and 13.22% for Ipca Laboratories. Over one year, Alkem Laboratories's share price is down 2.0% and Ipca Laboratories's is up 54.2%.
| Metric | Alkem Laboratories | Ipca Laboratories |
|---|---|---|
| NSE Symbol | ALKEM | IPCALAB |
| BSE Code | 539523 | 524494 |
| Share Price | ₹5,398.50 | ₹1,960.00 |
| Market Cap | ₹61,636 Cr | ₹49,470 Cr |
| P/E Ratio | 26.8 | 43.4 |
| Return on Equity | 17.56% | 13.22% |
| Return on Assets | 8.43% | 8.42% |
| Dividend Yield | 0.39% | 0.31% |
| Beta (1Y) | 0.29 | -0.04 |
| 1-Year Price Change | -2.0% | +54.2% |
| 3-Month Price Change | -3.6% | +16.3% |
| 52-Week Range | ₹4,811.00 – ₹5,933.50 | ₹1,293.90 – ₹2,038.00 |
| Latest Quarter | Q1 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹3,740 Cr | ₹2,910 Cr |
| Quarterly Net Profit | ₹521 Cr | ₹389 Cr |
| Net Margin | 13.9% | 13.4% |
| EPS (Basic, Quarter) | ₹43.49 | ₹14.79 |
| Results Basis | consolidated | consolidated |
| Headquarters | Mumbai, Maharashtra | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, rheumatology, urology, dermatology, cardiology, neu…
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, …
Alkem Laboratories has a market capitalisation of ₹61,636 Cr, against ₹49,470 Cr for Ipca Laboratories as of 9 Nov 2026, about 1.2 times the size by market cap.
Alkem Laboratories has a P/E of 26.8 and Ipca Laboratories a P/E of 43.4 as of 9 Nov 2026.
Alkem Laboratories has a return on equity of 17.56% and Ipca Laboratories 13.22%.
Alkem Laboratories's share price is down 2.0% over one year and Ipca Laboratories's is up 54.2%.
Alkem Laboratories reported revenue of ₹3,740 Cr and net profit of ₹521 Cr for Q1 FY27. Ipca Laboratories reported revenue of ₹2,910 Cr and net profit of ₹389 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.